Prostate Cancer

Immunotherapy-Chemo Combo Possible

NEW YORK—Immunotherapy with sipuleucel-T followed by docetaxel chemotherapy may prolong survival in patients with androgen-independent prostate cancer (AIPC), a researcher reported here at the Chemotherapy Foundation Symposium.

Medication Protects Bone in PCa Patients

PHILADELPHIA—Prostate cancer patients treated with luteinizing hormone- releasing hormone (LHRH) have increased bone turnover and rapid bone loss within six months. A recent study suggests that this can be prevented with risedronate 35 mg once a week.

Lower PSA Biopsy Cutoff Supported

African-American (AA) men with nonpalpable prostate cancer have greater cancer volumes and higher prostatectomy Gleason scores than white men with similar PSA levels at the time of biopsy, according to a study.

Continuing on Alendronate Beneficial

PHILADELPHIA—A second year of once-weekly treatment with alendronate continues to raise bone mass at the hip and spine and prevent bone loss in the distal radius in prostate cancer patients receiving androgen deprivation therapy, data show.

Androgen Deprivation Increases Risks

Treatment with a gonadotropin-releasing hormone (GnRH) agonist is associated with increased risks of diabetes, coronary heart disease (CHD), MI, and sudden cardiac death in men with prostate cancer, according to an observational study at Harvard Medical School in Boston.

ADT Use Increasing

Despite widespread early detection and aggressive treatment for prostate cancer in the United States, the use of androgen deprivation therapy (ADT) has been increasing, researchers reported in BJU International (2006;98:973-978).

Next post in News